Announcements
- Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
- Cue Biopharma to Host Business Update Call and Webcast
- Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
- Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
- Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
- Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
- Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
More ▼
Key statistics
As of last trade Cue Biopharma Inc (1UC:STU) traded at 1.48, 6.47% above its 52-week low of 1.39, set on Apr 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.50 |
---|---|
High | 1.52 |
Low | 1.48 |
Bid | 1.47 |
Offer | 1.56 |
Previous close | 1.47 |
Average volume | 0.00 |
---|---|
Shares outstanding | 48.64m |
Free float | 47.20m |
P/E (TTM) | -- |
Market cap | 76.86m USD |
EPS (TTM) | -1.11 USD |
Data delayed at least 15 minutes, as of Apr 18 2024.
More ▼